Prerequisite: EDMS 242 or EDSS 242 and EDMS 243 or EDSS 243 Cross listed: EDMS 244 *Click on the first column in each table row to see class details.

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

InductiveHealth today announced an exclusive partnership with Origami Risk, a global leader in risk, safety, and insurance SaaS technology.

There was an annualised relapse rate (ARR) of 0.04 in the study over that timeframe, and no change in disability measuring using the widely-used Expanded Disability Status Scale (EDSS).

The InductiveHealth EDSS is built for public health departments. It is broadly scalable, not reliant on costly custom development, and fully compliant with all CDC reporting guidelines.